HR 1079 109th Congress House Health Abortion Administrative procedure Commerce Congress Congressional investigations Congressional reporting requirements Congressional veto Department of Health and Human Services Drug approvals Drugs Food and Drug Administration (FDA) Government Operations and Politics Government publicity Labeling Law

RU-486 Suspension and Review Act of 2005

Introduced: March 3, 2005 See on congress.gov

Everywhere this bill has been 4 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 14, 2005

Referred to the Subcommittee on Health.

Mar 3, 2005

Referred to the House Committee on Energy and Commerce.

Mar 3, 2005

Sponsor introductory remarks on measure. (CR E357)

Mar 3, 2005

Introduced in House

Plain-English summary Congressional Research Service

RU-486 Suspension and Review Act of 2005 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.

Deems the drug misoprostol to be misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.

What's happening now March 14, 2005

Referred to the Subcommittee on Health.

Committees of jurisdiction 2